Intermittent Therapy for mHSPC in Low- and Middle-Income Countries: Aligning Deep PSA Responses With Sustainable Care

Default Digital Object Group 2026 Dataset

View at publisher
DOI: 10.1200/adn.26.300335
Cited by: 0

Abstract

Deep prostate-specific antigen suppression correlates with better survival outcomes in metastatic hormone-sensitive prostate cancer. Using prostate-specific antigen–guided intermittent therapy may help reduce toxicity and financial burden without compromising efficacy.

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Bone health and treatments

Publication details

Journal / source
Default Digital Object Group
Publication date
12 February 2026
Language
EN
Document type
Dataset